Emerging guidelines for diagnosing and treating asthma COPD overlap syndrome will help clinicians better manage patients and prevent serious adverse effects.
The designation was granted to Revive Therapeutics, a company that specializes in cannabis-based pharmaceuticals.
In patients with aspirin exacerbated respiratory disease, treatment with omalizumab resulted in "clinically silent" aspirin desensitization.
Budesonide-formoterol as needed was not inferior compared with budesonide maintenance therapy in terms of severe asthma exacerbation rates, but may be inferior for controlling symptoms.
There was a 60% lower rate of severe asthma exacerbations in individuals treated with budesonide-formoterol compared with individuals treated with terbutaline as needed.
Early clinical response rates were similar across PORT risk class subgroups in patients with community-acquired bacterial pneumonia when treated with omadacycline or moxifloxacin.
PCV13, marketed as Prevnar 13, was evaluated in a test-negative case-control study in real-world conditions where patients were administered pneumococcal vaccination as advised by their healthcare providers.
Liberal supplemental oxygen therapy in acutely ill patients increased mortality during hospitalization, at 30 days, and at longest follow-up.
In the LEAP 2 study (N=738), patients with moderate CABP received either oral lefamulin 600mg every 12 hours for 5 days or oral moxifloxacin 400mg once daily for 7 days.
In patients with acute respiratory failure, high-flow nasal cannula and conventional oxygen therapy provided similar benefits.
Tiotropium may be more effective in reducing the rate of moderate and severe chronic obstructive pulmonary disorder exacerbations when used in combination with olodaterol vs tiotropium alone.
Researchers evaluated barrier dysfunction by exposing viral models to budesonide, montelukast, formoterol, or a combination.
Inhaled interferon-beta 1 a did not significantly reduce acute asthma exacerbations during respiratory viral infections.
In this study, researchers examined the appropriateness of diagnosis and treatment of chronic obstructive pulmonary disease in individuals with and without HIV.
Inhaled corticosteroids for asthma dosed once daily in the evening appeared to offer some benefit in trough FEV1 and morning peak expiratory flow.
Steroid dosing and glucose levels were not associated with an increase in hospital readmissions related to COPD exacerbations.
The pooled safety analysis included data from the TRILOGY, TRINITY, and TRIBUTE studies.
Incident diuretic use was associated with increased rates of respiratory-related morbidity and mortality in older adults with chronic obstructive pulmonary disease.
Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
In individuals with asthma and vitamin D deficiency, vitamin D supplementation improved asthma control.